ST-1898 tablets

DRUG3 trials

Sponsors

Beijing Scitech-Mq Pharmaceuticals Limited

Conditions

Advanced Renal Cell CarcinomaDifferentiated Thyroid CarcinomaUnresectable or Metastatic Melanoma

Phase 1

Study of ST-1898 in Advanced Renal Cell Carcinoma

Active, not recruitingNCT06127238

Beijing Scitech-Mq Pharmaceuticals LimitedAdvanced Renal Cell Carcinoma

Start: 2023-02-07End: 2025-12-31Target: 90Updated: 2025-08-24

A Study of ST-1898 for Unresectable or Metastatic Melanoma

RecruitingNCT06359860

Beijing Scitech-Mq Pharmaceuticals LimitedUnresectable or Metastatic Melanoma

Start: 2023-11-07End: 2026-12-31Target: 64Updated: 2025-08-24

Phase 2

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

RecruitingNCT06359847

Beijing Scitech-Mq Pharmaceuticals LimitedDifferentiated Thyroid Carcinoma

Start: 2023-11-15End: 2027-12-31Target: 60Updated: 2025-08-24